ClinicalTrials.gg
RecruitingNCT06033703Updated Oct 16, 2026

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

A Phase 1/2 interventional study of Netarsudil Ophthalmic in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Massachusetts Eye and Ear Infirmary. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Massachusetts Eye and Ear Infirmary · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Vitreoretinopathy, Proliferative with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Vitreoretinopathy, Proliferative · United States.

Planned enrollment
8th of 12
48 · median 69
Started
2025
the only one that year
Phase 1/2
Only one
of the 12
Registered
11th of 12
by date
Lead sponsor
1 of 12
Massachusetts Eye and Ear Infirmary

Among the 12 studies in Vitreoretinopathy, Proliferative with a site in United States, this one is the 8th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 1/2, and was the 11th registered.

Vitreoretinopathy, Proliferative

43 studies on the registry are indexed under Vitreoretinopathy, Proliferative; 11 are open to participants now.

Browse Vitreoretinopathy, Proliferative studies →

Open to participants now

2 of the 12 studies in Vitreoretinopathy, Proliferative with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Vitreoretinopathy, Proliferative studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Vitreoretinopathy, Proliferative with a site in United States, or all of them as a file.
02

Study summary

This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes.

The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.

Read the detailed description

This is an open-label, randomized study that will test the safety and pharmacokinetics of topical netarsudil at a dose frequency of once-daily in two cohorts of patients: those with primary rhegmatogenous detachments, and those with established proliferative vitreoretinopathy. The intervention will be topical application of Netarsudil from time of diagnosis of retinal detachment to 16 weeks post-operatively.

Patients will be randomized to one of the following groups:

  • The primary rhegmatogenous detachment cohort: A total of 24 study subjects (24 eyes) will be stratified by their lens status (12 phakic versus 12 pseudophakic). All patients will receive once per day dosing of netarsudil.
  • The proliferative vitreoretinopathy cohort: A total of 24 study subjects (24 eyes) will be stratified by their lens status (12 phakic versus 12 pseudophakic). All patients will receive once per day dosing of netarsudil.

After surgery, patients will continue on once per day dosing of Netarsudil for a total of 16 weeks post-op.

03

Conditions studied

  • Rhegmatogenous Retinal Detachment
  • Proliferative Vitreoretinopathy

Keywords

  • Vitrectomy
  • Netarsudil
  • Pharmacokinetics
  • Safety
  • Efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The primary rhegmatogenous detachment cohort will have the following selection criteria:

Inclusion criteria:

  • Patients > 18 years old
  • Patients presenting for primary rhegmatogenous retinal detachment repair within 28 days of symptom onset
  • Patients undergoing vitrectomy or vitrectomy with scleral buckle

Exclusion criteria:

  • Patient unable to give consent
  • Patient unable to follow-up
  • Prior history of retinal detachment incisional surgery in presenting eye
  • Prior history of open globe injury to presenting eye
  • Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery, actively on glaucoma medication
  • Prior history of corneal disease, or history of corneal edema
  • Patient already on topical netarsudil in presenting eye
  • Patient without natural lens or intraocular lens implant (I.e., aphakic patients)
  • Patients with intraocular pressure \<8mm Hg in operative eye
  • Active or chronic or recurrent uncontrolled ocular or systemic disease
  • Active or history of chronic or recurrent inflammatory eye disease
  • Diagnosis of proliferative diabetic retinopathy
  • Signs of ocular infection at presentation in either eye
  • Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively
  • Inability to use/ apply topical eye drops

The proliferative vitreoretinopathy cohort will have the following selection criteria:

Inclusion criteria:

  • Patients > 18 years old
  • Patient presenting with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma
  • Patients undergoing vitrectomy or vitrectomy with scleral buckle

Exclusion criteria:

  • Patient unable to give consent
  • Patient unable to follow-up
  • Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery
  • Patient already on topical netarsudil in presenting eye
  • Patients with intraocular pressure \<8mm Hg in operative eye
  • Active or chronic or recurrent uncontrolled ocular or systemic disease
  • Active or history of chronic or recurrent inflammatory eye disease
  • Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in operative eye
  • Signs of ocular infection at presentation in either eye
  • Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively
  • Inability to use/ apply topical eye drops
  • No Light Perception vision in operative eye
  • Failure to achieve intraoperative reattachment
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Primary retinal detachment, Phakic group

    Phakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.

    Drug: Netarsudil Ophthalmic

  • Experimental
    Primary retinal detachment, Pseudophakic group

    Pseudophakic patients with primary rhegmatogenous retinal detachment repair within 7 days of symptom onset, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.

    Drug: Netarsudil Ophthalmic

  • Experimental
    Secondary retinal detachment, Phakic group

    Phakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.

    Drug: Netarsudil Ophthalmic

  • Experimental
    Secondary retinal detachment, Pseudophakic group

    Pseudophakic patients with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma, undergoing vitrectomy or vitrectomy with scleral buckle will be included. Patients will receive topical Netarsudil ophthalmic solution 0.02%: once per day, from time of diagnosis of retinal detachment to 16 weeks post-operatively.

    Drug: Netarsudil Ophthalmic

Interventions

06

What researchers measure

Primary outcomes

  1. The concentration of netarsudil in the vitreous to assess its pharmacokinetic properties.

    Netarsudil concentration in the posterior segment of the eye, using High-performance liquid chromatography (HPLC)

    Time frame: Through study completion, an average of 1 year

  2. Serious adverse events

    Unexpected serious adverse events

    Time frame: Day 1, 7, 28, 84, and 168 after surgery

Secondary outcomes

  1. Number of operations within 3 months

    Total number of operation during the first 3 months after surgery

    Time frame: Day 84 after surgery

  2. Final attachment status at last follow-up

    Status of the retina (attached versus detached) at last follow-up visit

    Time frame: Day 168 after surgery

  3. Visual acuity

    Best-corrected visual acuity measured using Snellen chart

    Time frame: Day 1, 7, 28, 84, and 168 after surgery

  4. Spectral domain optical coherence tomography (SD-OCT) of the macula

    Status of the macula (mac-on versus mac-off)

    Time frame: Day 1, 7, 28, 84, and 168 after surgery

  5. Adverse events

    Adverse events including conjunctival injection, subconjunctival hemorrhage, and corneal verticillata, eye irritation, reticular edema of the cornea, hypotony

    Time frame: Day 1, 7, 28, 84, and 168 after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lin CW, Sherman B, Moore LA, Laethem CL, Lu DW, Pattabiraman PP, Rao PV, deLong MA, Kopczynski CC. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):40-51. doi: 10.1089/jop.2017.0023. Epub 2017 Jun 13. PubMed 28609185 ↗
  • Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, Sheng H, Lewis RA, Heah T, Kopczynski CC. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. J Glaucoma. 2020 Oct;29(10):878-884. doi: 10.1097/IJG.0000000000001634. PubMed 32826769 ↗
  • Davies E, Jurkunas U, Pineda R 2nd. Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy. Cornea. 2021 Jul 1;40(7):899-902. doi: 10.1097/ICO.0000000000002691. PubMed 33758139 ↗
  • Kahook MY, Serle JB, Mah FS, Kim T, Raizman MB, Heah T, Ramirez-Davis N, Kopczynski CC, Usner DW, Novack GD; ROCKET-2 Study Group. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmol. 2019 Apr;200:130-137. doi: 10.1016/j.ajo.2019.01.003. Epub 2019 Jan 15. PubMed 30653957 ↗
  • Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC; ROCKET-1 and ROCKET-2 Study Groups. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-127. doi: 10.1016/j.ajo.2017.11.019. Epub 2017 Dec 1. PubMed 29199013 ↗
  • Fernandez MM. Reticular Epithelial Edema in Edematous Corneas Treated with Netarsudil. Ophthalmology. 2018 Nov;125(11):1709. doi: 10.1016/j.ophtha.2018.08.004. No abstract available. PubMed 30318038 ↗
  • Wisely CE, Liu KC, Gupta D, Carlson AN, Asrani SG, Kim T. Reticular Bullous Epithelial Edema in Corneas Treated with Netarsudil: A Case Series. Am J Ophthalmol. 2020 Sep;217:20-26. doi: 10.1016/j.ajo.2020.04.002. Epub 2020 Apr 11. PubMed 32289295 ↗
  • LoBue SA, Moustafa GA, Vu A, Amin M, Nguyen T, Goyal H. Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review. Cornea. 2021 Aug 1;40(8):1048-1054. doi: 10.1097/ICO.0000000000002621. PubMed 33369939 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2025 (actual). Primary completion is estimated for Sep 2028, 43 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Sep 2026 → Sep 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Sep 13, 2023
StartActual
Jan 14, 2025
Primary completionEst.
Sep 1, 2028was Sep 2026
CompletionEst.
Dec 2028was Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 1, 2028
Oct 16, 2026
Study completion
Dec 2026→Dec 2028
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Sep 2026→Sep 1, 2028
    Study completion Dec 2026→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06033703
Responsible party
Leo Am Kim, M.D. (Assistant Professor of Ophthalmology, Massachusetts General Hospital) — Principal investigator
First posted
Sep 13, 2023
Start date
Jan 14, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Leo Kim, MD, PhD
Contact
Leo_Kim@meei.harvard.edu
6175237900
Center for Clinical Research Operations (CCRO)
Contact
6175736060
Leo Kim, MD, PhD
principal investigator · Massachusetts Eye and Ear

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion